WO2000051605A1 - Compositions and methods for treating atopic dermatitis, angioedema and other disorders using antihistamines and glucocorticoids - Google Patents
Compositions and methods for treating atopic dermatitis, angioedema and other disorders using antihistamines and glucocorticoids Download PDFInfo
- Publication number
- WO2000051605A1 WO2000051605A1 PCT/US1999/004502 US9904502W WO0051605A1 WO 2000051605 A1 WO2000051605 A1 WO 2000051605A1 US 9904502 W US9904502 W US 9904502W WO 0051605 A1 WO0051605 A1 WO 0051605A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- allergic
- substituted
- antihistamine
- glucocorticoid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention generally relates to compositions and methods for treating atopic dermatitis, angioedema, urticaria, allergic rhinitis and other such disorders. It specifically discloses compositions comprising therapeutically effective amounts of antihistamines such as, for example, loratadine, and glucocorticoids such as, for example, betamethasone, for such treatment.
- antihistamines such as, for example, loratadine
- glucocorticoids such as, for example, betamethasone
- Atopic dermatitis is a chronic, itching, superficial inflammation of the skin, usually found in individuals with a history of allergic disorders. (The Merck Manual of Diagnosis and Therapy, D. Holvey ed., published by Merck & Co., Inc., Rahway,
- Angioedema and urticaria are local wheals and erythema in the dermis and can be due to causes such as, for example, drug allergy, insect bites and the like, ibid, page 241.
- Atopic dermatitis is generally managed by applying ointments or pastes of topical corticosteroids. Itching is generally relieved by antihistamines, often in large doses. Initially useful medicaments may generally become ineffective and must be replaced. Acute urticaria is often managed by oral antihistamines; corticosteroid treatment may be occasionally necessary particularly when associated with angioedema.
- Topical corticosteroids are generally of no value.
- Products containing a combination of a steroid and an antihistamine are known and available.
- a product containing chlorfeniramine maleate and paramethasone is available under the tradename DILARMINE ® from Roche Pharmaceuticals, Nutley, New Jersey.
- DILARMINE ® from Roche Pharmaceuticals, Nutley, New Jersey.
- the antihistamines in such products are typically sedating. There may be situations where sedating antihistamines are not acceptable.
- compositions and methods of treatment for diseases such as atopic dermatitis, angioedema, urticaria, seasonal and allergic rhinitis, food and drug allergies, allergic contact dermatitis, seborrhoic dermatitis, neurodermatitis, allergic asthma, ocular allergic manifestations such as conjunctivitis and iridociclitis, allergic reaction to insect stings and bites and other such disorders.
- diseases such as atopic dermatitis, angioedema, urticaria, seasonal and allergic rhinitis, food and drug allergies, allergic contact dermatitis, seborrhoic dermatitis, neurodermatitis, allergic asthma, ocular allergic manifestations such as conjunctivitis and iridociclitis, allergic reaction to insect stings and bites and other such disorders.
- compositions and methods of treatment for such diseases using an effective amount of a combination of one or more antihistamines, which are substantially non-sedating, with one or more glucocorticoids.
- compositions to treat diseases such as, for example, atopic dermatitis, angioedema, urticaria, seasonal and allergic rhinitis, food and drug allergies, allergic contact dermatitis, seborrhoic dermatitis, neurodermatitis, allergic asthma, ocular allergic manifestations such as conjunctivitis and iridociclitis, allergic reaction to insect stings and bites and other such disorders.
- diseases such as, for example, atopic dermatitis, angioedema, urticaria, seasonal and allergic rhinitis, food and drug allergies, allergic contact dermatitis, seborrhoic dermatitis, neurodermatitis, allergic asthma, ocular allergic manifestations such as conjunctivitis and iridociclitis, allergic reaction to insect stings and bites and other such disorders.
- the composition comprises in combination: (i) a therapeutically effective amount of one or more substantially non-sedating antihistamines or a pharmaceutically acceptable salt or solvate of such antihistamine(s) and (ii) a therapeutically effective amount of one or more glucocorticoid or a suitable derivative thereof.
- the present invention additionally discloses a method for the treatment of the above-noted diseases in a mammalian organism in need of such treatment, such treatment comprising administering a pharmaceutical composition described above.
- antihistamines useful in the practice of the present invention correspond to the general Formula I:
- X represents a halogen atom or a hydrogen atom
- Y represents hydrogen, -COORi or -SO 2 R 2
- Ri represents a substituted or unsubstituted alkyl group, a substituted or unsubstituted cycloalkyl group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted aryl group, or a substituted or unsubstituted heterocyclic ring
- R 2 represents a substituted or unsubstituted cycloalkyl group, or substituted or unsubstituted aryl group.
- substituted refers to appropriate substitution with moieties such as, for example, alkyl, aryl, aralkyl, alkylaryl, cycloalkyl, heterocyclic, halogen, ester, amide, ether, carbonyl, sulfonyl and the like.
- the compounds of Formula I embrace optical isomers and mixtures thereof, racemic mixtures, enol forms and other such modifications.
- Preferred compounds belonging to Formula I are those in which X is a halogen atom or a hydrogen atom, and Y is hydrogen or -COORi, where Ri is defined above. More particularly preferred compounds of this class are when X is Cl and Ri, is carboethoxy
- the compounds of Formula I can be prepared in accordance with processes known in the art, for example, that disclosed in U.S. Patents 3,326,924 and 4,282,233.
- DCL is described, for example, in U.S. Patent 4,659,716 and is a metabolic derivative of loratadine.
- Glucocorticoids generally belong to a class of steroid hormones that are synthesized by the adrenal cortex of vertebrates and have anti-inflammatory activity. Many are well known.
- the glucocorticoids useful in the practice of the present invention include, for example, prednisolone, prednisone, betamethasone, dexamethasone, fluoromethalone, medrysone, triamcinolone, hydrocortisone, prednicarbate, deflazacort, halomethasone, tixocortol, predinylidene (21- diethylaminoacetate), prednival, paramethasone, methylprednisolone, meprednisone, mazipredone, isoflupredone, halopredone acetate, halcinonide, formocortal, flurandrenolide, fluprednisolone, fluprednine acetate, fluperolone acetate, fluocor
- glucocorticoids include betamethasone, prednisolone, prednisone, flumethasone and hydrocortisone. Most preferred is betamethasone. Loratadine has been extensively studied for its antihistaminic effects and is considered to be a safe antihistamine as a H t antagonist. It is also considered to be an antihistamine without clinically significant sedative effects. It has also been proven to be safe and effective for the treatment of several respiratory and dermatologic allergic diseases. Betamethasone (Formula II) is a synthetic fluorinated derivative of hydrocortisone and has antiinflammatory properties. Betamethasone has been
- the present invention generally discloses novel pharmaceutical compositions comprising a substantially non-sedating antihistamine and a glucocorticoid. Additionally, there may be other optional ingredients present such as, for example, a pharmaceutically acceptable carrier. Still additional ingredients may also be present, especially depending on the form of administration of the pharmaceutical composition, as detailed later.
- the antihistamine or its pharmacologically acceptable salt or solvate is generally present in the composition in about 2-20 milligrams per dosage, preferably in about 2-10 milligrams and typically in about 3-7 milligrams.
- the glucocorticoid is generally present in the composition in about 0.02-1 milligram per dosage, preferably in about 0.02-0.8 milligrams and typically in about 0.03-0.5 milligram.
- the weight ratio of the glucocorticoid and antihistamine is in the range between about 1 : 100 and 1 :10.
- a pharmaceutically acceptable carrier (which includes diluents, excipients or carrier materials) may also be present in the composition.
- the carrier is suitably selected with respect to the intended form of administration, i.e. oral tablets, capsules (either solid-filled, semi-solid filled or liquid filled), powders for constitution, oral gels, elixirs, solutions, syrups, suspensions, and the like, and consistent with conventional pharmaceutical practices.
- the active ingredients i.e., the antihistamine and the glucocorticoid
- any oral non-toxic pharmaceutically acceptable inert carrier such as lactose, starch, sucrose, cellulose, magnesium stearate, dicalcium phosphate, calcium sulfate, mannitol, ethyl alcohol
- suitable binders include starch, gelatin, natural sugars, corn sweeteners, natural and synthetic gums such as acacia, sodium alginate, carboxymethylcellulose, polyethylene glycol and waxes.
- Suitable lubricants that may be mentioned for use in these dosage forms include, for example, boric acid, sodium benzoate, sodium acetate, sodium chloride, and the like.
- Disintegrants include starch, methylcellulose, guar gum and the like.
- Disinfectants include benzalkonium chloride and the like. Sweetening and flavoring agents and preservatives as well as other ingredients such as, for example, sodium croscarmellose, may also be included where appropriate.
- the present invention discloses a method of preparing a composition for use in the treatment of diseases such as, for example, atopic dermatitis, angioedema, urticaria, seasonal and allergic rhinitis, food and drug allergies, allergic contact dermatitis, seborrhoic dermatitis, neurodermatitis, allergic asthma, ocular allergic manifestations such as conjunctivitis and iridociclitis, allergic reaction to insect stings and bites and other such disorders, with the composition comprising a therapeutically effective amount of one or more substantially non-sedating antihistamines, or a pharmaceutically acceptable salt or solvate of such antihistamine, and one or more therapeutically effective glucocorticoid, optionally in combination with a pharmaceutically acceptable carrier.
- diseases such as, for example, atopic dermatitis, angioedema, urticaria, seasonal and allergic rhinitis, food and drug allergies, allergic contact dermatitis, seborrhoic dermatitis
- the present invention discloses a method of administering an effective treatment for diseases such as, for example, atopic dermatitis, angioedema, urticaria, seasonal and allergic rhinitis, food and drug allergies, allergic contact dermatitis, seborrhoic dermatitis, neurodermatitis, allergic asthma, ocular allergic manifestations such as conjunctivitis and iridociclitis, allergic reaction to insect stings and bites and other such disorders, the administration comprising administering a pharmaceutical composition described above.
- the pharmaceutical compositions of the present invention can be administered depending upon the patient's age, sex, weight and severity of the condition being treated.
- the human oral dosage form containing the antihistamine and the carrier can be administered 1 or 2 times per day.
- this invention discloses a method for the treatment of diseases such as, for example, atopic dermatitis, angioedema, urticaria, seasonal and allergic rhinitis, food and drug allergies, allergic contact dermatitis, seborrhoic dermatitis, neurodermatitis, allergic asthma, ocular allergic manifestations such as conjunctivitis and iridociclitis, allergic reaction to insect stings and bites and other such disorders in a mammalian organism in need of such treatment, such treatment comprising administering a therapeutically effective amount of one or more substantially non-sedating antihistamines, or a pharmaceutically acceptable salt or solvate of such antihistamine, and one or more therapeutically effective glucocorticoid, optionally in combination with a pharmaceutically acceptable carrier.
- diseases such as, for example, atopic dermatitis, angioedema, urticaria, seasonal and allergic rhinitis, food and drug allergies, allergic contact dermatitis, seborrho
- compositions of the present invention may be formulated in sustained release form to provide the rate controlled release of any one or more of the components or active ingredients to optimize the therapeutic effects.
- Suitable dosage forms for sustained release include layered tablets containing layers of varying disintegration rates or controlled release polymeric matrices impregnated with the active components and shaped in tablet form or capsules containing such impregnated or encapsulated porous polymeric matrices.
- Dosage form - refers to composition containing the antihistamine, the glucocorticoid and optionally a carrier formulated into a delivery system, i.e., tablet, capsule, oral gel, powder for constitution or suspension in association with inactive ingredients.
- a delivery system i.e., tablet, capsule, oral gel, powder for constitution or suspension in association with inactive ingredients.
- Capsule - refers to a special container or enclosure made of methyl cellulose, polyvinyl alcohols, or denatured gelatins or starch for holding or containing compositions comprising the active ingredients and optionally the carrier.
- Hard shell capsules are typically made of blends of relatively high gel strength bone and pork skin gelatins. The capsule itself may contain small amounts of dyes, opaquing agents, plasticizers and preservatives.
- Tablet- refers to a compressed or molded solid dosage form containing the active ingredients with suitable diluents.
- the tablet can be prepared by compression of mixtures or granulations obtained by wet granulation, dry granulation or by compaction.
- Oral gels refers to the active ingredients and the carrier dispersed or solubilized in a hydrophilic semi-solid matrix.
- Powders for constitution refers to powder blends containing the active ingredients and the carrier and suitable diluents which can be suspended in water or juices.
- Diluent - refers to substances that usually make up the major portion of the composition or dosage form. Suitable diluents include sugars such as lactose, sucrose, mannitol and sorbitol; starches derived from wheat, corn, rice and potato; and celluloses such as microcrystalline cellulose. The amount of diluent in the composition can range from about 2 to about 98% by weight of the total composition.
- Disintegrants refers to materials added to the composition to help it break apart (disintegrate) and release the medicaments.
- Suitable disintegrants include starches; "cold water soluble" modified starches such as sodium carboxymethyl starch; natural and synthetic gums such as locust bean, karaya, guar, tragacanth and agar; cellulose derivatives such as methylcellulose and sodium carboxymethylcellulose; microcrystalline celluloses and cross-linked microcrystalline celluloses such as croscarmellose sodium; alginates such as alginic acid and sodium alginate; clays such as bentonites; and effervescent mixtures.
- the amount of disintegrant in the composition can range from about 1 to about 15% by weight of the composition.
- Binders - refers to substances that bind or "glue” powders together and make them cohesive by forming granules, thus serving as the "adhesive" in the formulation.
- Binders add cohesive strength already available in the diluent or bulking agent.
- Suitable binders include sugars such as sucrose; starches derived from wheat, corn, rice and potato; natural gums such as acacia, gelatin and tragacanth; derivatives of seaweed such as alginic acid, sodium alginate and ammonium calcium alginate; cellulosic materials such as cellulose, methylcellulose, sodium carboxymethylcellulose and hydroxypropylmethylcellulose; polyvinylpyrrolidone; and inorganics such as magnesium aluminum silicate.
- the amount of binder in the composition can range from about 2 to about 98% by weight of the composition.
- Lubricant - refers to a substance added to the dosage form to enable the tablet, granules, etc. after it has been compressed, to release from the mold or die by reducing friction or wear.
- Suitable lubricants include metallic stearates such as magnesium stearate, calcium stearate or potassium stearate; stearic acid; high melting point waxes; and water soluble lubricants such as sodium chloride, sodium benzoate, sodium acetate, sodium oleate, polyethylene glycols and d'1-leucine. Lubricants are usually added at the very last step before compression, since they must be present on the surfaces of the granules and in between them and the parts of the tablet press. The amount of lubricant in the composition can range from about 0.05 to about 5% by weight of the composition.
- Suitable glidents include silicon dioxide and talc.
- the amount of glident in the composition can range from about 0.1 % to about 5% by weight of the total composition.
- Coloring agents - excipients that provide coloration to the composition or the dosage form. Such excipients can include food grade dyes and food grade dyes adsorbed onto a suitable adsorbent such as clay or aluminum oxide. The amount of the coloring agent can vary from about 0.1 to about 5% by weight of the composition.
- Bioavailability - refers to the rate and extent to which the active drug ingredient or therapeutic moiety is absorbed into the systemic circulation from an administered dosage form as compared to a standard or control, as well as to topical bioavailability.
- Conventional methods for preparing tablets are known. Such methods include dry methods such as direct compression and compression of granulation produced by compaction, or wet methods or other special procedures.
- the phrase "therapeutically effective amount” means that amount of the active ingredients which provides a therapeutical benefit in the treatment or management of the diseases stated above by the present inventive composition.
- a prophylactic or therapeutic dose of the active ingredients in the acute or chronic management of the targeted disease or condition will vary with the severity of the condition to be treated and the route of administration.
- the dose, and perhaps the dose frequency will also vary according the age, body weight, and response of the individual patient. Suitable total daily dose ranges can be readily determined by those skilled in the art.
- the dose may be administered in single or divided doses orally, topically, transdermally, or locally by inhalation. It is further recommended that children, patients aged over 65 years, and those with impaired renal or haptic function initially receive low doses, and that they then be titrated based on individual response(s) or blood level(s).
- any suitable route of administration may be employed for providing the patient with an effective dosage of the active ingredients according to the methods of the present invention.
- Some such routes are, for example, oral, intraoral, rectal, parenteral, epicutaneous, transdermal, subcutaneous, intramuscular, intranasal, sublingual, intradural, intraocular, intrarespiratory, oral or nasal inhalation and the like.
- Oral administration is preferred.
- pharmaceutically acceptable salt refers to a salt prepared from pharmaceutically acceptable non-toxic acids or bases including inorganic acids or bases or organic acids or bases.
- organic acids examples include hydrochloric, hydrobromic, hydriodic, sulfuric, and phosphoric.
- Appropriate organic acids may be selected, for example, from aliphatic, aromatic, carboxylic and sulfonic classes of organic acids, examples of which are formic, acetic, propionic, succinic, glycolic, glucuronic, maleic, furoic, glutamic, benzoic, anthranilic, salicylic, phenylacetic, mandelic, embonic (pamoic), methanesulfonic, ethanesulfonic, pantothenic, benzenesulfonic, stearic, sulfanilic, algenic, and galacturonic.
- inorganic bases include metallic salts made from aluminum, calcium, lithium, magnesium, potassium, sodium, and zinc.
- Appropriate organic bases may be selected, for example, from N,N-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, meglumaine (N-methylgulcaine), lysine and procaine.
- pharmaceutically acceptable solvate which, however, includes a solvent, water and the like as the solvating medium.
- dosage forms include tablets, troches, dispersions, suspensions, solutions, capsules, patches, syrups, elixirs, gels, powders, magmas, lozenges, ointments, creams, pastes, plasters, lotions, discs, suppositories, nasal or oral sprays, aerosols and the like. Because of their ease of administration, tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are employed. If desirable, tablets may be coated by standard aqueous or nonaqueous techniques.
- Another preferred dosage form is as liquid or solution, comprising the active ingredients along with any additional optional ingredient or ingredients in a pharmaceutically acceptable carrier which is preferably a liquid.
- compositions for use in the methods of the present invention may be prepared by any of the methods of pharmacy, but all methods include the step or steps of bringing into association the active ingredients and any optional ingredient or ingredients, carrier and the like.
- the compositions are prepared by uniformly and intimately admixing the active ingredients with liquid carriers or finely divided solid carriers or both, and then, if necessary, shaping the product into the desired presentation.
- a tablet may be prepared by compression or molding, optionally with one or more accessory ingredients.
- Compressed tablets may be prepared by compressing in a suitable machine the active ingredients in a free-flowing form such as powder or granules, optionally mixed with a binder, lubricant, inert diluent, surface active or dispersing agent. Molded tablets may be made by molding, in a suitable machine, a mixture of the powdered compound moistened with an inert liquid diluent.
- composition containing loratadine and betamethasone for a tablet and preparation of a tablet by a compression molding process may be illustrated as in the following Table I:
- Loratadine 2-10 Lactose monohydrate (LACTOSE FASTFLO ® ) 55-290
- Tablet weight 60-300 mg.
- ingredients may be admixed in any suitable order and converted into a tablet by suitable methods such as, for example, the methods stated earlier.
- betamethasone (0.25 mg) and loratadine (5 mg) were premixed with one portion (70 mg) of Lactose FASTFLO ® (available from Foremost Farm USA, Baraboo, Wisconsin).
- Lactose FASTFLO ® available from Foremost Farm USA, Baraboo, Wisconsin.
- the mix was then passed through a Quadro CoMil ® mill (a sieve mill available from Quadro, Waterloo, Ontario, Canada) equipped with a 20 mesh screen.
- lactose FASTFLO ® 71.75 mg
- croscarmellose sodium (2 mg) were then added and blended.
- AVICEL PH301 ® is a microcrystalline cellulose, available from FMC Corporation Pharmaceutical Division, City of Industry, California; Kollidon VA64 ® is a modified polyvinyl pyrrolidone available from BASF
- Cellulose microcrystalline e.g., AVICEL PH301 ®
- AVICEL PH301 ® 55-290 Kollidon VA64 ® 1-5 Kollidon CL ® 2-10
- loratadine 5 mg
- betamethasone 0.25 mg
- Kollidon VA64 ® 3 mg
- cellulose 84.65 mg
- Kollidon CL ® 7 mg
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Otolaryngology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU30652/99A AU3065299A (en) | 1999-03-01 | 1999-03-01 | Compositions and methods for treating atopic dermatitis, angioedema and other disorders using antihistamines and glucocorticoids |
EP99912236A EP1049471A1 (en) | 1999-03-01 | 1999-03-01 | Compositions and methods for treating atopic dermatitis, angioedema and other disorders using antihistamines and glucocorticoids |
PCT/US1999/004502 WO2000051605A1 (en) | 1999-03-01 | 1999-03-01 | Compositions and methods for treating atopic dermatitis, angioedema and other disorders using antihistamines and glucocorticoids |
BR9909368-5A BR9909368A (en) | 1999-03-01 | 1999-03-01 | Compositions and methods for the treatment of atopic dermatitis, angioedema and other disorders using antihistamines and glucocorticoids |
JP51714399A JP2001510485A (en) | 1999-03-01 | 1999-03-01 | Compositions and methods for treating atopic dermatitis, angioedema and other disorders using antihistamines and glucocorticoids |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US1999/004502 WO2000051605A1 (en) | 1999-03-01 | 1999-03-01 | Compositions and methods for treating atopic dermatitis, angioedema and other disorders using antihistamines and glucocorticoids |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000051605A1 true WO2000051605A1 (en) | 2000-09-08 |
Family
ID=22272279
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1999/004502 WO2000051605A1 (en) | 1999-03-01 | 1999-03-01 | Compositions and methods for treating atopic dermatitis, angioedema and other disorders using antihistamines and glucocorticoids |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1049471A1 (en) |
JP (1) | JP2001510485A (en) |
AU (1) | AU3065299A (en) |
WO (1) | WO2000051605A1 (en) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001026658A2 (en) * | 1999-10-08 | 2001-04-19 | Schering Corporation | Topical nasal treatment using desloratadine |
EP1670427A2 (en) * | 2003-09-15 | 2006-06-21 | CombinatoRx, Incorporated | Methods and reagents for the treatment of immunoinflammatory disorders |
WO2006112556A1 (en) * | 2005-04-21 | 2006-10-26 | Kyowa Hakko Kogyo Co., Ltd. | Method for treating cancer using premedication |
WO2008148572A1 (en) * | 2007-06-08 | 2008-12-11 | Bayer Consumer Care Ag | Anti-inflammatory active ingredient combination for the treatment of diseases of the skin and mucous membranes |
WO2009070431A1 (en) * | 2007-11-27 | 2009-06-04 | Harry Dugger | Antihistamine/corticosteroid preparations for the treatment of atopic dermatitis |
US20120171126A1 (en) * | 2009-06-16 | 2012-07-05 | Purakkattle Biju J | NOVEL [3,2-c] HETEROARYL STEROIDS AS GLUCOCORTICOID RECEPTOR AGONISTS COMPOSITIONS AND USES THEREOF |
WO2014085884A1 (en) | 2012-12-03 | 2014-06-12 | Ems S.A. | Pharmaceutical composition comprising desloratadine and prednisolone and use thereof |
US8822477B2 (en) | 2003-07-03 | 2014-09-02 | Bitop Ag | Use of osmolytes obtained from extremophilic bacteria for producing medicine for the external treatment of neurodermatitis |
WO2022119428A1 (en) | 2020-12-04 | 2022-06-09 | Laboratorios Silanes S.A. De C.V. | Pharmaceutical combination of a corticosteroid and an antihistamine for the treatment and control of the inflammatory component of allergic processes |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004069267A1 (en) * | 2003-02-10 | 2004-08-19 | Novartis Ag | Pharmaceutical combinations comprising corticoids and immunosuppressants for treating corticoid- and/or calcineurin inhibitors-resistant diseases |
MXPA06013384A (en) * | 2004-05-19 | 2007-03-01 | Emisphere Tech Inc | Topical cromolyn formulations. |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0704206A1 (en) * | 1994-09-30 | 1996-04-03 | Jürgen Dr. Regenold | Pharmaceutical composition |
EP0780127A1 (en) * | 1995-12-19 | 1997-06-25 | The Procter & Gamble Company | A nasal spray containing a steroid and a antihistamine |
-
1999
- 1999-03-01 EP EP99912236A patent/EP1049471A1/en not_active Withdrawn
- 1999-03-01 JP JP51714399A patent/JP2001510485A/en not_active Ceased
- 1999-03-01 AU AU30652/99A patent/AU3065299A/en not_active Abandoned
- 1999-03-01 WO PCT/US1999/004502 patent/WO2000051605A1/en not_active Application Discontinuation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0704206A1 (en) * | 1994-09-30 | 1996-04-03 | Jürgen Dr. Regenold | Pharmaceutical composition |
EP0780127A1 (en) * | 1995-12-19 | 1997-06-25 | The Procter & Gamble Company | A nasal spray containing a steroid and a antihistamine |
Non-Patent Citations (2)
Title |
---|
JEAL W. ET AL.: "Triamcinolone acetonide. A review of its pharmacological properties and therapeutic efficacy in the management of allergic rhinitis", DRUGS, vol. 53, no. 2, February 1997 (1997-02-01), pages 257 - 280, XP002121955 * |
RATNER P. H., ET AL.: "A comparison of the efficacy of fluticasone propionate aqueous nasal spray and loratadine, alone and in combination, for the treatment of seasonal allergic rhinitis", JOURNAL OF FAMILY PRACTICE, vol. 47, no. 2, August 1998 (1998-08-01), pages 118 - 125, XP002121956 * |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001026658A2 (en) * | 1999-10-08 | 2001-04-19 | Schering Corporation | Topical nasal treatment using desloratadine |
WO2001026658A3 (en) * | 1999-10-08 | 2002-02-21 | Schering Corp | Topical nasal treatment using desloratadine |
US8822477B2 (en) | 2003-07-03 | 2014-09-02 | Bitop Ag | Use of osmolytes obtained from extremophilic bacteria for producing medicine for the external treatment of neurodermatitis |
EP1670427A2 (en) * | 2003-09-15 | 2006-06-21 | CombinatoRx, Incorporated | Methods and reagents for the treatment of immunoinflammatory disorders |
EP1670427A4 (en) * | 2003-09-15 | 2009-01-07 | Combinatorx Inc | Methods and reagents for the treatment of immunoinflammatory disorders |
WO2006112556A1 (en) * | 2005-04-21 | 2006-10-26 | Kyowa Hakko Kogyo Co., Ltd. | Method for treating cancer using premedication |
WO2008148572A1 (en) * | 2007-06-08 | 2008-12-11 | Bayer Consumer Care Ag | Anti-inflammatory active ingredient combination for the treatment of diseases of the skin and mucous membranes |
WO2009070431A1 (en) * | 2007-11-27 | 2009-06-04 | Harry Dugger | Antihistamine/corticosteroid preparations for the treatment of atopic dermatitis |
US20120171126A1 (en) * | 2009-06-16 | 2012-07-05 | Purakkattle Biju J | NOVEL [3,2-c] HETEROARYL STEROIDS AS GLUCOCORTICOID RECEPTOR AGONISTS COMPOSITIONS AND USES THEREOF |
WO2014085884A1 (en) | 2012-12-03 | 2014-06-12 | Ems S.A. | Pharmaceutical composition comprising desloratadine and prednisolone and use thereof |
WO2022119428A1 (en) | 2020-12-04 | 2022-06-09 | Laboratorios Silanes S.A. De C.V. | Pharmaceutical combination of a corticosteroid and an antihistamine for the treatment and control of the inflammatory component of allergic processes |
Also Published As
Publication number | Publication date |
---|---|
JP2001510485A (en) | 2001-07-31 |
AU3065299A (en) | 2000-09-21 |
EP1049471A1 (en) | 2000-11-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4893305B2 (en) | Enhancement of the activity and / or duration of action of soft anti-inflammatory steroids for topical or other topical administration | |
JP2012001558A (en) | Novel combination of loteprednol and antihistamine | |
US4945089A (en) | Use of tetrahydrocortexolone to prevent elevations in intraocular pressure caused by corticosteroids | |
US20030191096A1 (en) | Method of hormonal therapy | |
WO2000051605A1 (en) | Compositions and methods for treating atopic dermatitis, angioedema and other disorders using antihistamines and glucocorticoids | |
JPH0334934A (en) | Use of statin derivative in eye disease therapy | |
JP2005526843A (en) | Methods for increasing therapeutic response to electroconvulsive therapy (“ECT”) | |
US6423721B1 (en) | Methods and compositions for treating sinusitis, otitis media and other related disorders using antihistamines | |
US7776846B2 (en) | Enhancement of activity and/or duration of action of selected anti-inflammatory steroids for topical or other local application | |
JP5278313B2 (en) | Transporter-enhanced corticosteroid activity | |
JP2011506607A (en) | Therapies for the treatment of immunoinflammatory disorders | |
AU2016294185B2 (en) | Estrogen receptor β partial agonist having estrogen receptor α inhibitory effect, and therapeutic agent for gynecological disorders using same | |
US7786101B2 (en) | Cardiovascular protection using anti-aldosteronic progestins | |
US5358943A (en) | Use of tetrahydrocortisol to prevent elevations in intraocular pressure caused by corticosteroids | |
MXPA99002272A (en) | Compositions and methods for the treatment of atopic dermatitis, angioedema and other disorders using antihistamines and glucocorticoi | |
US20020028793A1 (en) | Use of estrogens and delta-gonadien-21-3,20-diones | |
WO2000015226A1 (en) | Antihistamines for treating non-infective sinusitis or otitis media | |
CN101987103A (en) | Ophthalmic composition of carbonic anhydrase inhibitor | |
CN101987104A (en) | Ophthalmic composition of heteroaryl sulfamoyl carboxylic ester carbonic anhydrase inhibitor | |
JP2002543136A (en) | Use of antiprogestagens in combination therapy | |
HO et al. | ADRENALINE ANALOGUES | |
WO1999016450A1 (en) | Budesonide for the treatment of cholestatic liver diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: IN/PCT/1999/1/KOL Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999912236 Country of ref document: EP |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GD GE HR HU ID IL IN IS JP KG KR KZ LC LK LR LT LU LV MD MG MK MN MX NO NZ PL PT RO RU SE SG SI SK SL TJ TM TR TT UA US UZ VN YU |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWP | Wipo information: published in national office |
Ref document number: 1999912236 Country of ref document: EP |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1999912236 Country of ref document: EP |